Daytrading August 17 pre-market, page-25

  1. 2,223 Posts.
    lightbulb Created with Sketch. 32
    IVX nice announcement

     Invion completes study of INV103 (ala-Cpn10) in patients with systemic lupus (SLE)
     Study designed to test safety and biochemical effect of materially higher doses than previous studies
     Data from patients’ cells show positive effect after one month of dosing
     Study supports larger, longer trials of Cpn10 in patients with autoimmune diseases
     Company to focus on partnering the drug asset

    going up....
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.